Feuerstein's Biotech-Stock Mailbag
Happy New Year and welcome back to the Biotech Mailbag, version 2008.
Let's get right to your emails. D.M. writes: "Happy new year! I know your opinion of Medarex (MEDX) in the $15's. How do you feel about it in the $10's?"
Medarex isn't a favorite stock of mine, but I do think it's more attractive at $10 than $15.
Clearly, the market sees through whatever positive spin Medarex is putting on the recent phase III data for its melanoma drug ipilimumab. The stock's drop to $10 is discounting the likelihood of near-term approval.Ipilimumab as a monotherapy just doesn't seem to be effective enough on melanoma. Medarex insists that it will seek FDA approval based on the monotherapy data. I have no reason to doubt they will file, but I don't see investors giving them much credit for it. I think the drug's best shot at success in melanoma is in combination trials, which are ongoing. From a fundamental perspective, and talking to institutional investors who were short Medarex going into last month's data release, I didn't get the sense that there was much of an appetite to stay short below $10. Medarex does have a deep pipeline and a long list of development partners, so there is some value here. Plus, there's always the possibility that Medarex gets acquired.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV